Examinando por Autor "Montesinos, Rosa"

Seleccione resultados tecleando las primeras letras
Mostrando 1 - 4 de 4
  • Miniatura
    PublicaciónAcceso abierto
    A Functional Assessment Tool to Distinguish Controls From Alzheimer’s Disease in Lima, Peru
    (SAGE PUBLICATIONS INC, 2022) Custodio, Nilton; Montesinos, Rosa; Chambergo-Michilot, Diego; Herrera-Perez, Eder; Pintado-Caipa, Maritza; Seminario, Wendy; Cuenca, Jose; Mesía, Laura; Failoc-Rojas, Virgilio E; Diaz, Monica M
    Background: The Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale is a versatile functional assessment tool for patients with Alzheimer’s disease (AD). We evaluated its performance in controls, Peruvians with MCI or AD. Methods: A cross-sectional study of older adults attending a neurology institute in Lima (Peru) with mild cognitive impairment (MCI), AD or cognitively healthy. Test-retest reliability (intraclass correlation coefficient, ICC; internal consistency, Cronbach’s alpha) and validity were assessed. Results: We enrolled 276 individuals (AD: 113, MCI: 68, controls: 95) with no age, sex, educational level, and depressive symptom differences. Reliability was ideal (ICC: .996), and Cronbach’s alpha was adequate (.937). The ADCS-ADL could not differentiate MCI from controls but did differentiate AD severity. The ADCS-ADL correlated highly with nearly all tools. Conclusions: The ADCS-ADL scale is reliable in a population with AD in Lima, Peru. Future work may validate a tool for Peruvians with lower educational levels.
  • Miniatura
    PublicaciónAcceso abierto
    A Functional Assessment Tool to DistinguishControls From Alzheimer’s Disease in Lima,Peru
    (SAGE Publications Inc., 2022-06-03) Custodio, Nilton; Montesinos, Rosa; Chambergo-Michilot, Diego; Herrera-Perez, Eder; Pintado-Caipa, Maritza; Seminario, Wendy; Cuenca, José; Mesía, Laura; Failoc-Rojas, Virgilio E; Diaz, Monica M
    Background:The Alzheimer’s Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale is a versatile functionalassessment tool for patients with Alzheimer’s disease (AD). We evaluated its performance in controls, Peruvians with MCI orAD.Methods:A cross-sectional study of older adults attending a neurology institute in Lima (Peru) with mild cognitive impairment(MCI),ADor cognitively healthy. Test-retest reliability (intraclass correlation coefficient, ICC; internal consistency, Cronbach’salpha) and validity were assessed.Results:We enrolled 276 individuals (AD: 113, MCI: 68, controls: 95) with no age, sex, educational level, and depressivesymptom differences. Reliability was ideal (ICC: .996), and Cronbach’s alpha was adequate (.937). The ADCS-ADL could notdifferentiate MCI from controls but did differentiateADseverity. The ADCS-ADL correlated highly with nearly all tools.Conclusions:The ADCS-ADL scale is reliable in a population withADin Lima, Peru. Future work may validate a tool forPeruvians with lower educational levels.
  • Miniatura
    PublicaciónAcceso abierto
    Combining visual rating scales to identify prodromal Alzheimer's disease and Alzheimer's disease dementia in a population from a low and middle-income country
    (FRONTIERS MEDIA SA, 2022-09-01) Custodio, Nilton; Malaga, Marco; Chambergo-Michilot, Diego; Montesinos, Rosa; Moron, Elizabeth; Vences, Miguel A.; Huilca , José Carlos; Lira, David; Failoc-Rojas, Virgilio E.; Diaz, Monica M.
    “Background: Many low- and middle-income countries, including Latin America, lack access to biomarkers for the diagnosis of prodromal Alzheimer's Disease (AD; mild cognitive impairment due to AD) and AD dementia. MRI visual rating scales may serve as an ancillary diagnostic tool for identifying prodromal AD or AD in Latin America. We investigated the ability of brain MRI visual rating scales to distinguish between cognitively healthy controls, prodromal AD and AD. Methods: A cross-sectional study was conducted from a multidisciplinary neurology clinic in Lima, Peru using neuropsychological assessments, brain MRI and cerebrospinal fluid amyloid and tau levels. Medial temporal lobe atrophy (MTA), posterior atrophy (PA), white matter hyperintensity (WMH), and MTA+PA composite MRI scores were compared. Sensitivity, specificity, and area under the curve (AUC) were determined. Results: Fifty-three patients with prodromal AD, 69 with AD, and 63 cognitively healthy elderly individuals were enrolled. The median age was 75 (8) and 42.7% were men. Neither sex, mean age, nor years of education were significantly different between groups. The MTA was higher in patients with AD (p < 0.0001) compared with prodromal AD and controls, and MTA scores adjusted by age range (p < 0.0001) and PA scores (p < 0.0001) were each significantly associated with AD diagnosis (p < 0.0001) but not the WMH score (p=0.426). The MTA had better performance among ages <75 years (AUC 0.90 [0.85–0.95]), while adjusted MTA+PA scores performed better among ages>75 years (AUC 0.85 [0.79–0.92]). For AD diagnosis, MTA+PA had the best performance (AUC 1.00) for all age groups. Conclusions: Combining MTA and PA scores demonstrates greater discriminative ability to differentiate controls from prodromal AD and AD, highlighting the diagnostic value of visual rating scales in daily clinical practice, particularly in Latin America where access to advanced neuroimaging and CSF biomarkers is limited in the clinical setting.“
  • Miniatura
    PublicaciónAcceso abierto
    Combining visual rating scales to identify prodromal Alzheimer's disease and Alzheimer's disease dementia in a population from a low and middle-income country
    (FRONTIERS MEDIA SA, 2022-09-01) Custodio, Nilton; Malaga, Marco; Chambergo-Michilot, Diego; Montesinos, Rosa; Moron, Elizabeth; Vences, Miguel A.; Huilca, José Carlos; Lira, David; Failoc-Rojas, Virgilio E.; Diaz, Monica M.
    “Background: Many low- and middle-income countries, including Latin America, lack access to biomarkers for the diagnosis of prodromal Alzheimer's Disease (AD; mild cognitive impairment due to AD) and AD dementia. MRI visual rating scales may serve as an ancillary diagnostic tool for identifying prodromal AD or AD in Latin America. We investigated the ability of brain MRI visual rating scales to distinguish between cognitively healthy controls, prodromal AD and AD. Methods: A cross-sectional study was conducted from a multidisciplinary neurology clinic in Lima, Peru using neuropsychological assessments, brain MRI and cerebrospinal fluid amyloid and tau levels. Medial temporal lobe atrophy (MTA), posterior atrophy (PA), white matter hyperintensity (WMH), and MTA+PA composite MRI scores were compared. Sensitivity, specificity, and area under the curve (AUC) were determined. Results: Fifty-three patients with prodromal AD, 69 with AD, and 63 cognitively healthy elderly individuals were enrolled. The median age was 75 (8) and 42.7% were men. Neither sex, mean age, nor years of education were significantly different between groups. The MTA was higher in patients with AD (p < 0.0001) compared with prodromal AD and controls, and MTA scores adjusted by age range (p < 0.0001) and PA scores (p < 0.0001) were each significantly associated with AD diagnosis (p < 0.0001) but not the WMH score (p=0.426). The MTA had better performance among ages <75 years (AUC 0.90 [0.85–0.95]), while adjusted MTA+PA scores performed better among ages>75 years (AUC 0.85 [0.79–0.92]). For AD diagnosis, MTA+PA had the best performance (AUC 1.00) for all age groups. Conclusions: Combining MTA and PA scores demonstrates greater discriminative ability to differentiate controls from prodromal AD and AD, highlighting the diagnostic value of visual rating scales in daily clinical practice, particularly in Latin America where access to advanced neuroimaging and CSF biomarkers is limited in the clinical setting.“